Free Trial
→ Why More Investors Are Using Family Trusts to Protect Their Wealth (From SmartAsset) (Ad)tc pixel
NASDAQ:COCP

Cocrystal Pharma 11/13/2023 Earnings Report

Cocrystal Pharma logo
$1.32 -0.11 (-7.69%)
Closing price 04:00 PM Eastern
Extended Trading
$1.32 +0.00 (+0.38%)
As of 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Cocrystal Pharma EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.47
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Cocrystal Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cocrystal Pharma Announcement Details

Quarter
Date
11/13/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cocrystal Pharma's next earnings date is estimated for Wednesday, November 12, 2025, based on past reporting schedules.

Conference Call Resources

Cocrystal Pharma Earnings Headlines

Cocrystal Pharma, Inc. Closes $4.7 Million Registered Direct Offering with Additional $8.3 Million Potential from Warrants
September 15 at 4:52 PM  |  quiverquant.comQ
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
September 15 at 4:30 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/15/3150405/0/en/cocrystal-pharma-inc-announces-closing-of-up-to-13-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules.html
$3,600 gold is nice ... but here’s what most gold bugs are missing
Gold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet.tc pixel
September 16 at 2:00 AM  |  Weiss Ratings (Ad)
Cocrystal Pharma announces up to $13M registered direct offering
September 12, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/cocrystal-pharma-announces-up-to-13m-registered-direct-offering/ar-AA1MqRos
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
September 12, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/12/3149259/0/en/cocrystal-pharma-inc-announces-up-to-13-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules.html
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
September 12, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/12/3149161/0/en/cocrystal-pharma-showcases-cdi-988-the-first-oral-antiviral-in-development-for-norovirus-infection-in-a-podium-presentation-at-the-international-calicivirus-conference.html
See More Cocrystal Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email.

About Cocrystal Pharma

Cocrystal Pharma (NASDAQ:COCP) (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections. Lead projects target influenza A and B polymerases as well as key enzymes in coronaviruses such as SARS-CoV-2. Additional research efforts are directed at antiviral targets in hepatitis B virus, norovirus and other emerging viral threats, reflecting Cocrystal’s commitment to addressing a broad spectrum of infectious diseases.

Founded in 2006 and headquartered in Bothell, Washington, Cocrystal Pharma leverages collaborations with academic institutions and contract research organizations to expand its drug discovery capabilities. The company maintains research laboratories in the Seattle area and operates a business development office in New York City to engage with strategic partners and investors globally.

Under the leadership of founder and Chief Executive Officer Kenneth T. Hitchcock, Ph.D., Cocrystal Pharma seeks to address unmet medical needs in antiviral therapy. By combining deep structural biology expertise with a scalable discovery engine, the company aims to advance novel antivirals poised to combat both seasonal outbreaks and future pandemic threats.

View Cocrystal Pharma Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles